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Abstract 
Antipsychotic drugs have been used effectively for the treatment of schizophrenia symptoms, 
but they are often associated with metabolic side effects such as weight gain and endocrine 
disruptions. To investigate the possible mechanisms of antipsychotic-induced metabolic 
effects, we studied the impact of chronic administration of a typical antipsychotic drug 
(haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body 
weight, adiposity, and the circulating concentrations of hormones and metabolites that can 
influence energy homeostasis. Chronic (28 days) haloperidol administration had no effect on 
food intake, weight gain or adiposity in male rats, whereas risperidone treatment resulted in a 
transient reduction in food intake and significantly reduced body weight gain compared to 
vehicle-treated control rats. Whereas neither antipsychotic had any effect on serum lipid 
profiles, glucose tolerance or the circulating concentrations of hormones controlled by the 
hypothalamo-pituitary-thyroid (free T4), -adrenal (corticosterone), -somatotropic (IGF-1), or -
gonadotropic axes (testosterone), haloperidol increased circulating insulin levels and 
risperidone increased serum glucagon levels. This finding suggests that haloperidol or 
risperidone induce distinct metabolic effects. Since metabolic disorders such as obesity and 
type 2 diabetes mellitus represent serious health issues, understanding antipsychotic-induced 
endocrine and metabolic effects may ultimately allow better control of these side effects. 
 
1. Introduction 
 Schizophrenia is a debilitating neuropsychiatric illness characterized by 
multidimensional phenotype with a profound disruption in cognition and emotion, along with 
negative (i.e. apathy, lack of emotion, poor or non-existent social functioning) and positive 
(i.e. hallucinations, delusions) symptoms. It affects approximately 1% of the population 
worldwide. The underlying aetiology of schizophrenia is still largely unknown, but it is likely to 
be a complex interplay between genetic predisposition and environmental effects (e.g. early 
developmental stressors). 
 Antipsychotic drugs have been used for the treatment of schizophrenia since the 
1950s. They can be categorized as either conventional (typical), such as chlorpromazine and 
haloperidol, or novel (atypical), such as clozapine, olanzapine, quetiapine, aripiprazole and 
risperidone, which were introduced after 1990. Typical drugs are efficient in reducing 
symptoms of psychosis but not particularly useful against negative symptoms or cognitive 
deficits. Atypical antipsychotic drugs have gained popularity over typical antipsychotics due to 
their efficacy in controlling not only psychotic (positive) but also negative symptoms. In 
addition, atypical antipsychotics induce fewer side effects such as extrapyramidal symptoms 
(EPS) including akathisia, dystonia and tardive dyskinesia. EPS are caused by the 
dopaminergic antagonism of antipsychotics (Green et al., 2000). Moreover, atypical 
antipsychotic drugs have been increasingly used for the clinical management of other 
conditions such as mania, bipolar disorder, dementia, and severe anxiety (Hellewell, 
2006 and Nemeroff, 2005). However, one serious disadvantage of atypical antipsychotic 
drugs is an increased propensity of excessive weight gain and diabetes mellitus associated 
with their use (Conley and Kelly, 2005, Green et al., 2000 and Henderson, 2001), although 
the degree of weight gain induced by the different atypical agents may range significantly. For 
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example, the atypical antipsychotics clozapine and olanzapine have been reported to induce 
substantial weight gain of approximately 4 kg over ten weeks period while others like 
sertindole and risperidone had more modest effects with mean weight gain of 2.92 kg and 
2.10 kg respectively after ten weeks of treatment (Allison et al., 1999). With regard to other 
metabolic side-effects, while both the typical antipsychotic haloperidol and the atypical drug 
risperidone have been linked with the development of diabetes mellitus, controversy exists 
over the risk of diabetes associated with their use (Feldman et al., 2004 and Miller et al., 
2005). 
 Antipsychotic-induced metabolic side effects such as weight gain and endocrine 
disruptions have important clinical implications as they significantly increase morbidity and 
mortality, reduce quality of life, interfere with medication compliance and increase the chance 
of psychotic relapse (Allison et al., 2003, Russell and Mackell, 2001 and Weiden et al., 2004). 
The mechanisms responsible for these antipsychotic-induced side effects are poorly 
understood. Since excess body weight is linked to insulin resistance and progression to type 
2-diabetes, it has been suggested that antipsychotics induce diabetes via increases in body 
weight and adiposity (Baptista et al., 2002a and Kato and Goodnick, 2001). However, obesity 
is not the only mechanism by which antipsychotics engender diabetes, since cases of newly 
diagnosed diabetes have been observed in lean people taking antipsychotics in the absence 
of weight gain, and withdrawal of certain antipsychotic drugs can normalize diabetes even 
before drug-induced effects on body weight are reversed (Clark and Burge, 2003 and Liberty 
et al., 2004). In addition, population studies in people taking antipsychotic drugs have shown 
the incidence of diabetes mellitus to be unrelated to the degree of weight gain (Farwell et al., 
2004). To further complicate understanding of the links between antipsychotic use, weight 
gain and diabetes in human studies, many people under treatment with antipsychotics have 
schizophrenia, and schizophrenia per se is associated with diabetes mellitus ( Feldman et al., 
2004 and Liberty et al., 2004). 
 Therefore in order to elucidate the possible mechanisms of antipsychotic-induced 
metabolic effects, we investigated the impact of chronic administration of a typical 
antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) on food intake, 
body weight, adiposity, and circulating hormone and metabolite levels in male rats. We have 
chosen haloperidol and risperidone as both are commonly used antipsychotics that produce 
low to moderate increases in body weight and are associated with diabetes mellitus risk in 
humans (Allison et al., 1999, Feldman et al., 2004, Liberty et al., 2004 and Miller et al., 2005). 
Both drugs act on multiple neurotransmitter receptors, although each drug can be 
characterized by a unique receptor binding profile (Goldstein, 2000). Haloperidol acts 
primarily on dopamine D2 receptors with lower activity at D1, D3, D4, 5-HT2A and α1 
adrenergic receptors (Goldstein, 2000 and Miyamoto et al., 2005). On the other hand, as with 
many atypical antipsychotics, risperidone possesses high serotonin (5-HT2A) receptor 
antagonism combined with relatively milder D2 receptor antagonism, compared to either its 
activity on 5-HT2A receptors or haloperidol's activity on D2 receptors (Goldstein, 2000, 
Megens et al., 1994 and Miyamoto et al., 2005). Current literature on the effects of 
haloperidol and risperidone on body weight gain and food intake vary, which is mostly likely 
due to the widely different drug treatment designs (dose and duration of drug treatment, mode 
of administration, diet composition, species and gender of experimental subjects). Haloperidol 
has been reported to increase body weight in female rats with or without increase in food 
intake (Fell et al., 2004, Fell et al., 2005 and Pouzet et al., 2003). Chronic risperidone 
treatment lead to increases in both body weight gain and food intake in female rats (Baptista 
et al., 2002b and Pouzet et al., 2003). A similar effect on body weight gain was observed in 
risperidone-treated female mice but without any accompanying increase in food intake (Cope 
et al., 2005). In contrast to the commonly observed body weight gain in female rodents, 
haloperidol or risperidone did not induce body weight gain in male rats (Baptista et al., 
2002b and Pouzet et al., 2003). However, the antipsychotic-induced effect on body weight is 
dose-sensitive, as another study reported body weight gain in male rats at low but not high 
doses of risperidone (Ota et al., 2002) and another study showed that female rats receiving a 
low dose of haloperidol (0.04 mg/kg/day) did not gain weight (Arjona et al., 2004). The 
mechanisms behind the antipsychotic induced weight gain in female but not male rodents 
were poorly understood but has been attributed to a selective interaction between the 
antipsychotics and female hormones (Baptista et al., 1997 and Baptista et al., 1998). 
 The observation that male rats do not gain excessive weight following chronic  
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treatment with haloperidol or risperidone provides a model to study the direct effect of these 
drugs on endocrine function and metabolic parameters independent of antipsychotic-induced 
weight gain. By understanding the primary hormonal and metabolic effects of different 
antipsychotic drugs we could gain insight into the aetiology of antipsychotic-induced weight 
gain and diabetes and therefore design better strategies to combat these serious side effects. 
 
2. Methods 
 
2.1. Animals and experimental design 
Male adult Sprague–Dawley rats (9–10 weeks of age, 357 ± 75 g at transfer; University of 
Adelaide Laboratory Animal Services, Adelaide, Australia) were kept under standard 
laboratory conditions of controlled temperature (22 °C) and illumination (12-h light cycle, lights 
on at 07:00 h). After transfer, rats were allowed to habituate to the new holding facility for 
seven days. Test animals were allocated to three experimental groups (n = 12 rats/group) 
which received one of the following infusions for 28 days: “vehicle”: osmotic minipump 
implants (Model 2ML4: Alzet, Palo Alto, CA, USA) loaded with vehicle (acetic acid solution 
adjusted to pH 5.0 ± 0.3); “haloperidol”: osmotic minipump implants loaded with haloperidol 
(0.4 mg/kg/day); “risperidone”: osmotic minipump implants loaded with risperidone 
(2.13 mg/kg/day). In this study, we used doses of haloperidol or risperidone that achieve 80% 
or greater D2 receptor occupancy, therefore producing extrapyramidal symptoms that prove 
drug release and action. Since risperidone achieves D2 receptor occupancy less readily than 
haloperidol, it was administered in proportionally higher doses (2.13 mg/kg/day) relative to 
haloperidol (0.4 mg/kg/day) ( Kapur and Remington, 2001, Kapur and Seeman, 2001, Kapur 
et al., 2003 and Wadenberg et al., 2001). This dosing regimen also takes into consideration 
the reported 4–6 times shorter half-life of antipsychotic drugs in rodents than humans and 
highlights the advantage of using minipumps in the present study for continuous drug 
administration to achieve receptor occupancies comparable to clinical use in humans (Kapur 
et al., 2003). Rats were group-housed (three rats of same treatment group per cage) and 
were fed a normal chow diet ad libitum (6% calories from fat, 21% calories from protein, 71% 
calories from carbohydrate, 2.6 kilocalories/g, Gordon's Speciality Stock Feeds, Yanderra, 
NSW, Australia). All research and animal care procedures were approved by the Garvan 
Institute/St Vincent's Hospital Animal Experimentation Ethics Committee and were in 
agreement with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purpose. All efforts were made to minimise animal suffering and reduce the number of 
animals used. 
 
2.2. Osmotic pump implantation and chronic drug administration 
Under halothane anaesthesia, minipumps were implanted subcutaneously on the upper back 
of rats. In brief, the upper back was shaved and a 1.5 cm long incision was made in the skin. 
The minipump was inserted under the skin into a subcutaneous pocket formed with forceps, 
which was then sewn shut with non-absorbable suture (3-0 Ethicon Prolene: Johnson & 
Johnson, New Brunswick, USA). The wound was treated with 5 mg/ml solution of bupivicaine 
(0.01 ml/100 g) before animals were returned to their home cage for recovery. 
 
2.3. Body weight and food intake measurement 
Body weight and food intake were measured daily for the first week following surgery. 
Subsequently, body weight was recorded twice per week on days 9, 13, 16, 20, 23 and 27 
post-surgery, and 24-h food intake was measured at day 2 to 7, day 14 and day 21 post-
surgery. Final body weight was obtained prior to cull on day 28. 
 
2.4. Glucose tolerance tests 
After 11–14 days of treatment, animals were fasted overnight and given an intraperitoneal 
injection of glucose (1 g/kg) using a 50% glucose solution (Astra Zeneca, North Ryde, 
Australia). Blood samples (10 µL) were collected from the tail vein of conscious unrestrained 
rats at 0, 15, 30, 45, 60, 75, 90 and 120 min following glucose injection, and blood glucose 
levels were measured using an AccuCheck™ blood glucose meter (Roche Diagnostics, 
Mannheim, Germany). 
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2.5. Tissue collection 
Twenty-eight days following minipump implantation, food was removed from cages at 08:00 h 
and rats were culled 3–6 h later by decapitation under halothane anaesthesia for collection of 
trunk blood. Right inguinal, right retroperitoneal, mesenteric and right epididymal white 
adipose tissue (WAT) depots, brown adipose tissue (BAT), pancreas, liver, right testis and 
right seminal vesicle were dissected out and weighed. Adipose tissue depots were weighed 
as an index of adiposity in the different groups of animals. The pancreas and liver were 
weighed because changes in the weight of these tissues can indicate changes in the 
regulation of energy homeostasis (e.g. altered hepatic glycogen or lipid storage significantly 
affect liver weight). Testis and seminal vesicle were weighed as an index of activity of the 
hypothalamo-pituitary-gonadotropic axis, which not only significantly affects the weight of 
these tissues (Pierroz et al., 1996) but also affects body composition (Mudali and Dobs, 
2004). 
 
2.6. Serum analysis 
Serum hormone and metabolite levels were determined with commercial assay kits from 
Roche Diagnostics (triglyceride), Linco Research (St Louis, MO) (glucagon, insulin), ICN 
Biomedicals (Costa Mesa, CA) (corticosterone, free T4, testosterone), Wako Pure Chemical 
Industries (Japan) (free fatty acid) and Bioclone Australia (Sydney, Australia) (insulin-like 
growth factor 1, IGF-1). Basal serum glucose levels were determined with a glucose oxidase 
kit (Trace Scientific, Melbourne Australia). 
 
2.7. Statistical analysis 
All data are expressed as means ± SE (standard error of the mean). Differences among 
groups of rats were assessed by ANOVA or repeated measure ANOVA followed by Fisher's 
PLSD post-hoc comparisons if appropriate (StatView version 4.51, Abacus Concepts, 
Berkeley, CA). Statistical significance was defined as P < 0.05. 
 
3. Results 
 
3.1. Effect of haloperidol or risperidone on body weight and food intake 
Initial body weights were not significantly different among the three experimental groups 
(vehicle, 375.6 ± 7.9 g; haloperidol, 374.9 ± 5.1 g; risperidone, 362.3 ± 8.8 g; F(2,31) = 1.031, 
p = 0.369). Repeated measures ANOVA revealed a significant difference in growth rate 
among groups (Fig. 1A, F(2,24) = 3.018, p < 0.0001), which was attributed to the slower 
growth rate in the risperidone treated group compared to the vehicle treated control and 
haloperidol treated rats (Fisher's PLSD, p < 0.0001 for both comparisons). This was 
illustrated by the marked difference in total body weight gain at the end of 28 days of infusion, 
with risperidone-treated rats gaining significantly less weight than both the vehicle-treated 
control group and the haloperidol-treated group (Fig. 1B, F(2,33) = 10.211, p = 0.0004; 
Fisher's PLSD, p < 0.001, risperidone vs. vehicle or p < 0.01 risperidone vs. haloperidol). No 
difference was observed between the haloperidol- and vehicle-treated control groups 
(Fisher's PLSD, p = 0.433). 
 An acute reduction in food intake relative to vehicle-infused animals was observed in 
risperidone-treated rats at day 2 (F(2,9) = 10.373, p < 0.01), day 4 (F(2,9) = 5.692, p < 0.05), 
day 6 (F(2,9) = 4.668, p < 0.05) and one week following minipump implantation (Fig. 1C, 
F(2,9) = 4.84, p < 0.05). This reduction was not observed at two or three weeks post-surgery 
(Fig. 1C, F(2,6) = 3.846, p = 0.084 and F(2,9) = 2.09, p = 0.180, respectively). Food intake 
was not significantly affected by haloperidol treatment (Fig. 1C). Repeated measures ANOVA 
did not reveal significant differences in food consumption over time between different drug 
treatment groups (F(2,14) = 1.25, p = 0.278). 
 
3.2. Effect of haloperidol or risperidone on glucose tolerance 
There was no difference among the three groups of rats with respect to fasting blood glucose 
levels or blood glucose levels measured at any time point during the glucose tolerance test 
(Fig. 2A, repeated measures ANOVA, F(2,14) = 1.133, p = 0.320), except for 90 min following 
glucose challenge when risperidone treated rats had slightly lower blood glucose than the 
other two groups (risperidone, 4.467 mM vs. vehicle or haloperidol, 4.775 mM, ANOVA, 
F(2,33) = 3.615, p < 0.05; Fisher's PLSD, p < 0.05). For area under the glycemic response  
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curves, neither antipsychotic treatment group was different to the vehicle-treated control 
group although there was a slight but significant difference between the two antipsychotic 
treatment groups, with higher glucose levels in the haloperidol group than in the risperidone 
group (Fig. 2B, F(2,33) = 3.314, p < 0.05; Fisher's PLSD, p < 0.05). 
 
3.3. Effect of haloperidol or risperidone on body tissue composition 
Absolute weights of the different white adipose tissue (WAT) deposits, brown adipose tissue 
(BAT) and organs were similar among groups except for a significant reduction in mesenteric  
Repeated measures ANOVA did not reveal significant differ-
ences in food consumption over time between different drug
treatment groups (F(2,14) ¼ 1.25, p ¼ 0.278).
3.2. Effect of haloperidol or risperidone on glucose
tolerance
There was no difference among the three groups of rats
with respect to fasting blood glucose levels or blood glucose
levels measured at any time point during the glucose
tolerance test (Fig. 2A, repeated measures ANOVA,
F(2,14) ¼ 1.133, p ¼ 0.320), except for 90 min following
glucose challenge when risperidone treated rats had slightly
lower blood glucose than the other two groups (risperidone,
4.467 mM vs. vehicle or haloperidol, 4.775 mM, ANOVA,
F(2,33) ¼ 3.615, p < 0.05; Fisher’s PLSD, p < 0.05). For
area under the glycemic response curves, neither antipsy-
chotic treatment group was different to the vehicle-treated
control group although there was a slight but significant dif-
ference between the two antipsychotic treatment groups,
with higher glucose levels in the haloperidol group than
in the risperidone group (Fig. 2B, F(2,33) ¼ 3.314, p < 0.05;
Fisher’s PLSD, p < 0.05).
3.3. Effect of haloperidol or risperidone on body tissue
composition
Absolute weights of the different white adipose tissue
(WAT) deposits, brown adipose tissue (BAT) and organs
were similar among groups except for a significant reduction
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Fig. 1. (A) Body weight change as a percentage of initial pre-surgery weights
following minipump implantation. Risperidone-treated rats were significantly
different to both vehicle and haloperidol treated rats (***p < 0.001). (B) Ab-
solute body weight gain following 28 days of vehicle or antipsychotic drug in-
fusion. Risperidone group had lower total body weight gain compared to
vehicle group (***p < 0.001) or haloperidol group (**p < 0.01). (C) 24-h
food intake following minipump implantation. Food intake was lower in ris-
peridone group compared to vehicle group or haloperidol group (*p < 0.05;
**p < 0.01). Data are presented as mean " SE.
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Fig. 2. (A) Changes in blood glucose after injection of a glucose solution
(1.0 g/kg). Time 0 corresponds to preload basal glucose after overnight fast-
ing. Serum glucose level was slightly lower in the risperidone group com-
pared to either vehicle or haloperidol at 90 min post glucose injection
(*p < 0.05). (B) The area under the curve was significantly different between
the haloperidol and risperidone groups (*p < 0.05) but not between the
vehicl group and either antipsychotic drug groups. Data are presented as
mean " SE.
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WAT (F(2,33) = 3.296, p < 0.05; Fisher's PLSD, p < 0.05 vs. haloperidol), pancreas 
(F(2,33) = 7.051, p < 0.01; Fisher's PLSD, p < 0.01 vs. vehicle or haloperidol) and liver 
(F(2,33) = 4.614, p < 0.05; Fisher's PLSD, p < 0.01 vs. vehicle) weights in the risperidone-
treated group (Table 1). However, these differences were proportionate to the low body 
weight gain observed in risperidone-treated rats, since tissue weights relative to body weight 
were similar across groups, except for a higher relative testis weight (F(2,33) = 4.775, 
p < 0.05; Fisher's PLSD, p < 0.01 vs. haloperidol) observed for the risperidone-treated group 
(Table 1). 
  
3.4. Hormonal and metabolic changes 
Although serum glucagon levels were increased in both treatment groups, only risperidone-
treated rats showed statistically significant change where glucagon increased four-fold 
compared to vehicle-treated controls (Table 2, F(2,16) = 4.791, p < 0.05, Fisher's PLSD, 
p < 0.01, risperidone vs. vehicle). Circulating insulin levels were also varied, with haloperidol- 
but not risperidone-treated rats exhibiting significantly higher serum insulin levels than those 
of the vehicle-treated control group (Table 2, F(2,33) = 3.486, p < 0.05, Fisher's PLSD, 
p < 0.05, haloperidol vs. vehicle). Neither haloperidol nor risperidone treatment affected 
serum concentrations of any of the other hormones or metabolites measured (Table 2). 
 
4. Discussion 
This study examined the effects of chronic subcutaneous infusion of supratherapeutic doses 
of a typical (haloperidol) and an atypical (risperidone) antipsychotic drugs on endocrine  
Repeated measures ANOVA did not reveal significant differ-
ences in food consumption over time between different drug
treatment groups (F(2,14) ¼ 1.25, p ¼ 0.278).
3.2. Effect of haloperidol or risperidone on glucose
tolerance
There was no difference among the three groups of rats
with respect to fasting blood glucose levels or blood glucose
levels measured at any time point during the glucose
tolerance test (Fig. 2A, repeated measures ANOVA,
F(2,14) ¼ 1.133, p ¼ 0.320), except for 90 min following
glucose challenge when risperidone treated rats had slightly
lower blood glucose than the other two groups (risperidone,
4.467 mM vs. vehicle or haloperidol, 4.775 mM, ANOVA,
F(2,33) ¼ 3.615, p < 0.05; Fisher’s PLSD, p < 0.05). For
area under the glycemic response curves, neither antipsy-
chotic treatment group was different to the vehicle-treated
control group although there was a slight but significant dif-
ference between the two antipsychotic treatment groups,
with higher glucose levels in the haloperidol group than
in the risperidone group (Fig. 2B, F(2,33) ¼ 3.314, p < 0.05;
Fisher’s PLSD, p < 0.05).
3.3. Effect of haloperidol or risperidone on body tissue
composition
Absolute weights of the different white adipose tissue
(WAT) deposits, brown adipose tissue (BAT) and organs
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Fig. 1. (A) Body weight change as a percentage of initial pre-surgery weights
following minipump implantation. Risperidone-treated rats were significantly
different to both vehicle and haloperidol treated rats (***p < 0.001). (B) Ab-
solute body weight gain following 28 days of vehicle or antipsychotic drug in-
fusion. Risperidone group had lower total body weight gain compared to
vehicle group (***p < 0.001) or haloperidol group (**p < 0.01). (C) 24-h
food intake following minipump implantation. Food intake was lower in ris-
peridone group compared to vehicle group or haloperidol group (*p < 0.05;
**p < 0.01). Data are presented as mean " SE.
B
A
0
2
4
6
8
10
12
0 20 40 60 80 100 120
Time (minutes)
G
lu
co
se
 (m
M
)
Vehicle
Haloperidol
Risperidone
580
600
620
640
660
680
700
720
740
760
Vehicle Haloperidol Risperidone
G
lu
co
se
 a
re
a 
(m
M
/m
in)
Fig. 2. (A) Changes in blood glucose after injection of a glucose solution
(1.0 g/kg). Time 0 corresponds to preload basal glucose after overnight fast-
ing. Serum glucose level was slightly lower in the risperidone group com-
pared to either vehicle or haloperidol at 90 min post glucose injection
(*p < 0.05). (B) The area under the curve was significantly different between
the haloperidol and risperidone groups (*p < 0.05) but not between the
vehicle group and either antipsychotic drug groups. Data are presented as
mean " SE.
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functions and metabolic profile in male Sprague–Dawley rats. Release and action of 
antipsychotic agents was confirmed by the observation of extrapyramidal symptoms such as 
a catalepsy-like phenotype and vacuous chewing movements as a model for tremor or tardive 
dyskinesia in humans, as published elsewhere (Karl et al., 2006). Chronic (28 days) 
haloperidol administration had no effect on food intake, weight gain or adiposity in male rats 
whereas risperidone treatment resulted in a transient reduction in food intake and significantly 
reduced body weight gain compared to vehicle-treated control rats. Whereas neither 
antipsychotic had any effect on serum lipid profiles, serum glucose concentrations, glucose 
tolerance, or the circulating concentrations of hormones controlled by the hypothalamo-
pituitary-thyroid (free T4), -adrenal (corticosterone), -somatotropic (IGF-1), or -gonadotropic 
axes (testosterone), the two antipsychotics had distinct effects on endocrine activities, with 
haloperidol increasing circulating insulin levels and risperidone increasing serum glucagon 
levels. 
 Although clinical use of haloperidol has been associated with modest weight gain in 
humans, we showed that increased body weight gain and hyperphagia are not immediate 
early effects of this drug in male rats. In keeping with this, body weight was not affected when 
haloperidol was administered orally to male rats for three or six weeks (Minet-Ringuet et al., 
2005 and Pouzet et al., 2003), and was even suppressed under the longer treatment period 
of 80 weeks (Yoshida et al., 1995). The early stages of obesity, indicated by an increase in 
percent body fat, have been observed even in the absence of increases in body weight or 
food intake (Kushi et al., 1998, Pedrazzini et al., 1998 and Sainsbury et al., 1997). This is due 
to preferential channelling of fuels from lean tissues such as muscle and bone towards white 
in mesenteric WAT (F(2,33) ¼ 3.296, p < 0.05; Fisher’s
PLSD, p < 0.05 vs. haloperidol), pancreas (F(2,33) ¼ 7.051,
p < 0.01; Fisher’s PLSD, p < 0.01 vs. vehicle or haloperidol)
and liver (F(2,33) ¼ 4.614, p < 0.05; Fisher’s PLSD, p < 0.01
vs. vehicle) weights in the risperidone-treated group (Table 1).
However, these differences were proportionate to the low body
weight gain observed in risperidone-treated rats, since tissue
weights relative to body weight were similar across groups,
except for a higher relative testis weight (F(2,33) ¼ 4.775,
p < 0.05; Fisher’s PLSD, p < 0.01 vs. haloperidol) observed
for the risperidone-treated group (Table 1).
3.4. Hormonal and metabolic changes
Although serum glucagon levels were increased in both
treatment groups, only risperidone-treated rats showed statisti-
cally significant change where glucagon increased four-fold
compared to vehicle-treated controls (Table 2, F(2,16) ¼
4.791, p < 0.05, Fisher’s PLSD, p < 0.01, risperidone vs.
vehicle). Circulating insulin levels were also varied, with
haloperidol- but not risperidone-treated rats exhibiting signif-
icantly higher serum insulin levels than those of the vehicle-
treated control group (Table 2, F(2,33) ¼ 3.486, p < 0.05,
Fisher’s PLSD, p < 0.05, haloperidol vs. vehicle). Neither hal-
operidol nor risperidone treatment affected serum concentra-
tions of any of the other hormones or metabolites measured
(Table 2).
4. Discussion
This study examined the effects of chronic subcutaneous in-
fusion of supratherapeutic doses of a typical (haloperidol) and
a atypical (risperidone) antipsychotic drugs on endocrine
functions and metabolic profile in male SpragueeDawley
rats. Release and action of antipsychotic agents was confirmed
by the observation of extrapyramidal symptoms such as a cat-
alepsy-like phenotype and vacuous chewing movements as
a model for tremor or tardive dyskinesia in humans, as pub-
lished elsewhere (Karl et al., 2006). Chronic (28 days) halo-
peridol administration had no effect on food intake, weight
gain or adiposity in male rats whereas risperidone treatment
resulted in a transient reduction in food intake and signifi-
cantly reduced body weight gain compared to vehicle-treated
control rats. Whereas neither antipsychotic had any effect on
serum lipid profiles, serum glucose concentrations, glucose
tolerance, or the circulating concentrations of hormones con-
trolled by the hypothalamo-pituitary-thyroid (free T4), -adre-
nal (corticosterone), -somatotropic (IGF-1), or -gonadotropic
axes (testosterone), the two antipsychotics had distinct effects
on endocrine activities, with haloperidol increasing circulating
insulin levels and risperidone increasing serum glucagon
levels.
Although clinical use of haloperidol has been associated
with modest weight gain in humans, we showed that increased
body weight gain and hyperphagia are not immediate early ef-
fects of this drug in male rats. In keeping with this, body
weight was not affected when haloperidol was administered
orally to male rats for three or six weeks (Minet-Ringuet
et al., 2005; Pouzet et al., 2003), and was even suppressed un-
der the longer treatment period of 80 weeks (Yoshida et al.,
1995). The early stages of obesity, indicated by an increase
in percent body fat, have been observed even in the absence
of increases in body weight or food intake (Kushi et al.,
1998; Pedrazzini et al., 1998; Sainsbury et al., 1997). This is
due to preferential channelling of fuels from lean tissues
such as muscle and bone towards white adipose tissue under
the influence of hormonal changes such as increased serum
levels of insulin (Cusin et al., 1990), corticosterone (Guil-
laume-Gentil et al., 1993) and growth hormone (Ho et al.,
1996) and reduced serum levels of thyroid hormones (Kyle
et al., 1966), IGF-1 (Shaw et al., 2003), and testosterone
(Mudali and Dobs, 2004). However, our data show that not
only does chronic haloperidol administration to male rats
have no effect on body weight or food intake, it also has no
effect on adiposity or the serum levels of many of the hor-
mones that modulate body composition.
Table 1
Body tissue absolute and relative weight following 28 days of antipsychotic
treatment, presented as mean " SE
Vehicle Haloperidol Risperidone
WAT inguinal (g) 3.18 " 0.19 3.37 " 0.20 2.78 " 0.16
(%) 0.69 " 0.03 0.75 " 0.04 0.68 " 0.03
WAT epididymal (g) 2.98 " 0.11 2.96 " 0.16 2.57 " 0.20
(%) 0.65 " 0.02 0.66 " 0.03 0.63 " 0.04
WAT mesenteric (g) 2.70 " 0.11 2.79 " 0.20 2.20 " 0.20#
(%) 0.59 " 0.02 0.62 " 0.04 0.53 " 0.04
WAT retroperitoneal (g) 2.32 " 0.16 2.54 " 0.21 2.18 " 0.18
(%) 0.51 " 0.03 0.57 " 0.04 0.53 " 0.03
BAT (g) 0.29 " 0.03 0.28 " 0.03 0.28 " 0.03
(%) 0.06 " 0.01 0.06 " 0.01 0.07 " 0.01
Pancreas (g) 1.47 " 0.04 1.43 " 0.06 1.20 " 0.07**##
(%) 0.32 " 0.01 0.32 " 0.01 0.29 " 0.01
Liver (g) 16.66 " 0.48 15.84 " 0.52 14.42 " 0.58**
(%) 3.64 " 0.07 3.54 " 0.08 3.54 " 0.09
Testes (g) 1.73 " 0.03 1.64 " 0.05 1.64 " 0.04
(%) 0.38 " 0.01 0.37 " 0.01 0.41 " 0.01##
Seminal vesicle (g) 0.73 " 0.04 0.67 " 0.05 0.67 " 0.04
(%) 0.16 " 0.01 0.15 " 0.01 0.17 " 0.01
**p < 0.01 compared to vehicle treated group; #p < 0.05, ##p < 0.01 com-
pared to haloperidol treated group.
Table 2
Serum hormone and metabolite levels following 28 days of antipsychotic treat-
ment, presented as mean " SE
Vehicle Haloperidol Risperidone
Glucagon (pM) 13.58 " 2.50 23.25 " 8.46 53.81 " 11.66**
Insulin (pM) 135.37 " 16.34 210.13 " 26.78* 165.18 " 15.34
Glucose (mM) 8.82 " 0.44 8.57 " 0.39 8.28 " 0.33
Triglyceride (mg/dL) 83.82 " 7.63 91.00 " 8.71 100.58 " 15.02
FFA (mEq/L) 0.28 " 0.04 0.31 " 0.04 0.26 " 0.03
Free T4 (pM) 24.60 " 0.77 27.37 " 0.93 25.21 " 0.84
Corticosterone (ng/mL) 160.23 " 18.42 159.93 " 19.61 161.20 " 29.48
IGF-1 (ng/mL) 792.79 " 31.65 820.60 " 42.46 716.83 " 42.16
Testosterone (nM) 4.87 " 0.78 4.03 " 0.57 3.54 " 0.78
*p < 0.05, **p < 0.01 compared to vehicle treated group.
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only does chronic haloperidol administration to male rats
have no effect on body weight or food intake, it also has no
effect on adiposity or the serum levels of many of the hor-
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adipose tissue under the influence of hormonal changes such as increased serum levels of 
insulin (Cusin et al., 1990), corticosterone (Guillaume-Gentil et al., 1993) and growth hormone 
(Ho et al., 1996) and reduced serum levels of thyroid hormones (Kyle et al., 1966), IGF-1 
(Shaw et al., 2003), and testosterone (Mudali and Dobs, 2004). However, our data show that 
not only does chronic haloperidol administration to male rats have no effect on body weight or 
food intake, it also has no effect on adiposity or the serum levels of many of the hormones 
that modulate body composition. 
 Basal circulating levels of insulin were significantly elevated by 1.5 fold in male rats 
after 28 days of haloperidol administration compared to vehicle-infused control rats. Others 
have reported a slight or non-significant increase in serum insulin levels following chronic 
haloperidol administration to male rats (Manzanares et al., 1988 and Minet-Ringuet et al., 
2005). This increase in circulating insulin has been suggested as one of the reasons 
preventing body weight gain in male rats treated with haloperidol (Baptista et al., 2002c), 
which follows Eckel's proposal that insulin resistance may be an adaptive response for weight 
maintenance (Eckel, 1992). While hyperinsulinemia, insulin resistance and dyslipidemia are 
often detected in people treated with antipsychotics (Clark and Burge, 2003 and Sacchetti 
et al., 2005), it is unclear whether these conditions are direct drug effects or are related to 
weight gain since many of these subjects have gained significant weight through the course 
of antipsychotic drug treatment. There were very few studies examining the effect of 
haloperidol treatment on insulin level in humans (Brambilla et al., 1975 and Brambilla et al., 
1976). While these human studies failed to show an impact of haloperidol on circulating 
insulin levels by 30 days of haloperidol treatment, interpretation of the data was limited due to 
the diabetes and hyperinsulinemia already present in these schizophrenia patients. 
Therefore, it was not possible from these studies to determine the direct effect of haloperidol 
on insulin secretion. Our results were unaffected by the potential diabetogenic effect of 
schizophrenia per se and demonstrate that hyperinsulinemia is a direct effect of haloperidol 
and not a secondary effect due to increased adiposity or weight gain. 
 Intriguingly, previous in vitro studies showed that haloperidol affects neither basal nor 
glucose-stimulated insulin secretion in pancreatic cells ( Best et al., 2005 and Melkersson, 
2004). However, haloperidol caused marked depolarisation of the membrane potential of rat 
pancreatic β cells in the presence of both low and high concentrations of glucose, and 
decreased cell input conductance, both of which could alter insulin secretion. Moreover, 
haloperidol was found to block the ATP-sensitive potassium (KATP) channels in rodent 
pancreatic β cells via interaction with the Kir6.2 subunit of the channel (Yang et al., 2004). In 
pancreatic β cells, closure of the KATP channels leads to membrane depolarisation, opening of 
voltage-gated calcium channels and a rise in intracellular calcium that triggers insulin 
secretion (for review, see Kanno et al., 2002). The reduction in channel open probability and 
prolonged closed time of KATP channels caused by haloperidol could be a potential 
mechanism by which this drug induces hyperinsulinemia. Interestingly, a recent report 
identified a mutation in the Kir6.2 subunit that lead to greatly reduced intrinsic open probability 
in congenital hyperinsulinism (Lin et al., 2006). Further studies are needed to resolve the 
discrepancy between the in vitro and in vivo data, which may in part due to a difference in 
acute and chronic drug administration and the doses of drug used. 
 Another mechanism by which haloperidol induced hyperinsulinemia may be linked to 
its antagonistic action on dopamine D2 receptors. Indeed, chronic administration of sulpiride, 
a dopamine D2–D3 receptor antagonist, leads to elevated circulating insulin and glucose 
levels in rats during a glucose tolerance test (Baptista et al., 2002c). In addition, dopamine 
D2-like receptors are expressed in both rat and human pancreatic β cells and mediate 
inhibition of glucose-stimulated but not basal insulin secretion (Rubi et al., 2005). However, it 
is interesting to note that the risperidone-treated rats did not increase basal serum insulin 
significantly despite high occupancy of D2 receptors at the dose used. 
 It is possible that haloperidol-induced hyperinsulinemia is a primary etiological factor 
in the development of dyslipidemia, increased adiposity, weight gain, insulin resistance, 
glucose intolerance, and eventual progression to diabetes mellitus (indicated by fasting 
hyperglycemia) in people under treatment with this typical antipsychotic drug. Excess insulin 
in animals and man has been shown to induce insulin resistance and fat accumulation (Cusin 
et al., 1990 and Marangou et al., 1986). Experimental reduction of insulinemia in 
hyperinsulinemic, obese, insulin resistant animal models of type 2-diabetes (leptin-deficient 
ob/ob mice and fa/fa rats) significantly reduced body weight, hepatic and adipose tissue 
lipogenesis, circulating triglyceride levels, and improved insulin sensitivity ( Assimacopoulos- 
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Jeannet and Jeanrenaud, 1976 and Standridge et al., 2000). Although we saw no evidence of 
progression to glucose intolerance, fasting hyperglycemia, dyslipidemia or increased 
adiposity in the rats chronically treated with haloperidol in this study, it would be interesting to 
see if longer-term treatment eventually engenders these hallmark characteristics of diabetes 
mellitus. 
 The atypical antipsychotic risperidone has been associated with weight gain and 
diabetes mellitus in clinical use. However, our current findings would argue against obesity or 
diabetes being early or direct effects of risperidone, since adiposity, glucose tolerance, serum 
lipid profiles, and the circulating concentrations of many of the hormones that regulate body 
composition were unaltered in male rats chronically treated with risperidone. On the contrary, 
we observed a significant reduction in body weight gain and early stage food intake in 
risperidone-treated male rats compared to vehicle-infused controls. This is in keeping with 
another study showing that 0.5 mg/kg/day risperidone reduced body weight gain in male rats, 
albeit lower doses (0.005 to 0.05 mg/kg/day) had the opposite effect (Ota et al., 2002). In 
another study, male rats treated subcutaneously with 0.125 to 0.5 mg/kg/day risperidone for 
16 days showed no change in food intake or body weight gain compared to control animals 
(Baptista et al., 2002b). Taken together, our data suggest that chronic risperidone treatment 
in rats at the current dose does not induce changes in food intake or hormonal/metabolic 
changes that could predispose to the development of obesity or diabetes mellitus. The 
metabolic side effects reported in people under treatment with risperidone could therefore be 
due to species-specific effects of this drug, confounding variables, or perhaps dose 
differences. 
 Unlike haloperidol, which significantly increased serum insulin levels, we observed no 
significant effect of risperidone on circulating insulin concentrations in rats. In contrast, 
risperidone but not haloperidol induced a marked and significant increase in serum 
concentrations of glucagon. From the current study it is not clear if this change is secondary 
to other effects of risperidone (such as weight loss), or whether the increased serum 
glucagon levels are a direct effect of risperidone on the glucagon-producing alpha cells of the 
islets of Langerhans. 
 In summary, this study has demonstrated distinct endocrine disturbances in male rats 
treated with the typical antipsychotic drug haloperidol or the atypical antipsychotic 
risperidone. Chronic administration of haloperidol for four weeks lead to an increase in basal 
serum insulin levels in the absence of increases in food intake, adiposity or body weight, 
whereas risperidone treatment resulted in reduced food intake, reduced body weight, and 
elevated serum glucagon levels. Our findings suggest that if haloperidol or risperidone 
induced metabolic side effects, these side effects would be due to different mechanisms. 
Since hyperinsulinemia may be involved in the development of increased adiposity, weight 
gain, glucose intolerance, type 2 diabetes mellitus and dyslipidemia in predisposed 
individuals, understanding the effects of antipsychotic-induced hyperinsulinemia may allow 
better control of these side-effects, particularly in patients with a family history of diabetes or 
obesity or a higher predisposition towards these disorders. 
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